Effects of a Selective Endothelin A Receptor Antagonist on the Expressions of iNOS and eNOS in the Heart of Early Streptozotocin-Induced Diabetic Rats

Abstract

Vascular tone is regulated through the actions of locally produced agents. Among the vasoconstrictors, the most potent agent is endothelin (ET), which exerts its vasoconstrictor actions principally through ET type A (ET_A) receptors. Of the vasodilators, nitric oxide (NO) seems to be the most important contributor to the acute regulation of vascular tone. Vasculopathy is an important feature of diabetes mellitus (DM). Endogenous ET-mediated vasoconstrictor tone is augmented in diabetic states, and conflicting results persist concerning the NO system in diabetes. The present study investigated the expressions of inducible NO synthases (iNOS) and endothelial NOS (eNOS) in the heart of diabetic animals and the effects of a selective ET_A receptor antagonist on these alterations. Type I diabetes was induced by intraperitoneal injection of streptozotocin (65 mg/kg) in Sprague-Dawley rats, while control (Con) rats received only citrate buffer. After 1 week, the streptozotocin-administered rats were randomly divided into two groups: the selective ET_A receptor antagonist–administered group (DM+TA-0201, 1 mg/kg/day, by osmotic minipump for 2 weeks) and the DM+vehicle group (comprising the diabetic rats that received saline). The random blood glucose level was 405 ± 103 mg/dl in DM animals, and this level was unchanged by ET antagonism. Body weight was more greatly decreased in DM rats than in Con rats, but the left ventricle to body weight ratio was increased in the DM group and was unaffected by ET antagonism. Protein expressions of eNOS and iNOS were assessed in the left ventricular tissues. eNOS expression was significantly increased in DM heart and was greatly inhibited by the treatment with ET antagonist. The expression of iNOS was also increased in early DM heart but was reversed by the ET antagonist. Thus, endothelin antagonism might be beneficial for DM heart by reversing the upregulated eNOS and iNOS expressions.

Get full access to this article

View all access options for this article.

References

Dubrey SW, Reaveley DR, Seed M, Lane DA, Ireland H, O’Donnell M, O’Connor B, Noble MI, Leslie RD. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes 43:831–835, 1994.

Rodrigues B, McNeill JH. Physiological and pathological consequences of streptozotocin diabetes on the heart. In: McNeill JH, Ed. Experimental Models of Diabetes. Boca Raton, FL: CRC Press, pp63–77, 1999.

Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Prog Cardiovasc Dis 27:255–270, 1985.

Chan NN, Vallance P, Colhoun HM. Nitric oxide and vascular responses in type I diabetes. Diabetologia 43:137–147, 2000.

Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051–3064, 1992.

Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2:997–1000, 1989.

Radomski MW, Salas E. Nitric oxide: biological mediator, modulator and factor of injury. Its role in the pathogenesis of atherosclerosis. Atherosclerosis 118:S69–S80, 1995.

Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 14:753–759, 1994.

De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 130:963–974, 2000.

10.

Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 30:535–560, 1990.

11.

Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 78:931–936, 1994.

12.

Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 100:2146–2152, 1997.

13.

Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 100:2417–2423, 1997.

14.

Iwashina M, Shichiri M, Marumo F, Hirata Y. Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. Circulation 98:1212–1218, 1998.

15.

Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 150:5080–5085, 1993.

16.

Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61:391–415, 1999.

17.

Hileeto D, Cukiernik M, Mukherjee S, Evans T, Barbin Y, Downey D, Karmazyn M, Chakrabarti S. Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes Metab Res Rev 18:386–394, 2002.

18.

Gallego M, Espina L, Casis O. Blood pressure responsiveness to sympathetic agonists in anaesthetised diabetic rats. J Physiol Biochem 58:87–93, 2002.

19.

Hebden RA, Bennett T, Gardiner SM. Pressor sensitivities to vasopressin, angiotensin II, or methoxamine in diabetic rats. Am J Physiol 253:R726–R734, 1987.

20.

Ishikawa T, Kohno F, Kawase R, Yamamoto Y, Nakayama K. Contribution of nitric oxide produced by inducible nitric oxide synthase to vascular responses of mesenteric arterioles in streptozotocin-diabetic rats. Br J Pharmacol 141:269–276, 2004.

21.

Katovich MJ, Hanley K, Strubbe G, Wright BE. Effects of streptozotocin-induced diabetes and insulin treatment on blood pressure in the male rat. Proc Soc Exp Biol Med 208:300–306, 1995.

22.

Fitzgerald SM, Brands MW. Nitric oxide may be required to prevent hypertension at the onset of diabetes. Am J Physiol Endocrinol Metab 279:E762–E768, 2000.

23.

Mattar AL, Fujihara CK, Ribeiro MO, de Nucci G, Zatz R. Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. Nephron 74:136–143, 1996.

24.

Pieper GM. Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 42:204–213, 1999.

25.

Stockklauser-Farber K, Ballhausen T, Laufer A, Rosen P. Influence of diabetes on cardiac nitric oxide synthase expression and activity. Biochim Biophys Acta 1535:10–20, 2000.

26.

Nagareddy PR, Xia Z, McNeill JH, Macleod KM. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol 289:H2144–H2152, 2005.

27.

El-Omar MM, Lord R, Draper NJ, Shah AM. Role of nitric oxide in posthypoxic contractile dysfunction of diabetic cardiomyopathy. Eur J Heart Fail 5:229–239, 2003.

28.

Felaco M, Grilli A, De Lutiis MA, Patruno A, Libertini N, Taccardi AA, Di Napoli P, Di Giulio C, Barbacane R, Conti P. Endothelial nitric oxide synthase (eNOS) expression and localization in healthy and diabetic rat hearts. Ann Clin Lab Sci 31:179–186, 2001.

29.

Bardell AL, MacLeod KM. Evidence for inducible nitric-oxide synthase expression and activity in vascular smooth muscle of streptozotocin-diabetic rats. J Pharmacol Exp Ther 296:252–259, 2001.

30.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 322:411–415, 1988.

31.

de Nucci G, Thomas R, D’Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 85:9797–9800, 1988.

32.

Hirata Y, Hayakawa H, Suzuki E, Kimura K, Kikuchi K, Nagano T, Hirobe M, Omata M. Direct measurements of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteration in salt-induced hypertension. Circulation 91:1229–1235, 1995.